We want to inform you about a recent update regarding Librela (bedinvetmab injection), a medication used to manage osteoarthritis pain in dogs. The FDA has provided updated guidance to ensure the medication’s safe use, which includes information about its post-approval experiences.
What You Should Know:
- Librela remains safe and effective: The injection targets a key pain mediator in the body and is used monthly to help manage chronic osteoarthritis pain in dogs.
- FDA Update: The FDA has updated the label for Librela to include additional information about potential adverse events reported from real-world use. These adverse events are rare and have been monitored closely.
- No recall or removal: The FDA has not issued a recall or removed Librela from the market. The update simply provides additional information based on post-approval data.
- New resources for pet owners: Zoetis, the manufacturer, has added a Client Information Sheet (CIS) with details on how to monitor your dog after receiving Librela, and when to contact your veterinarian.
What You Can Do:
- If your dog is currently using Librela, rest assured that it is still a safe and effective treatment.
- We recommend keeping an eye on your dog for any unusual symptoms after treatment and contacting us if you have concerns.
- If you’d like more information or have questions, we’re happy to discuss this update with you during your pet’s next visit.
Your pet’s health and well-being are our top priority, and we are here to support you with any concerns about their treatment.
For further information, feel free to contact us!
!Social Media Icons